Results 181 to 190 of about 8,868 (210)

Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. [PDF]

open access: yesCancer Immunol Immunother
Engels P   +17 more
europepmc   +1 more source

c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. [PDF]

open access: yesCell Rep Med
Balke-Want H   +25 more
europepmc   +1 more source

Preliminary screening of urinary host protein biomarkers for Schistosomiasis haematobium: A proteome profiling study identifying candidate diagnostic targets in school-aged children. [PDF]

open access: yesPLoS Negl Trop Dis
Liu Y   +12 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate

Blood, 2023
CD276 (B7-H3) is an immune checkpoint inhibitor expressed in a majority of solid tumors and hematologic malignancies, however it has not been well-described in acute myeloid leukemia (AML). A variety of immunotherapies targeting CD276 including CAR T cells and antibody-drug conjugates (ADCs) are being explored in solid tumors, however ...
Danielle C Kirkey   +11 more
openaire   +1 more source

CAR T cells recognizing CD276 and Dual-CAR T cells against CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

2023
AbstractBackgroundRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood, whose prognosis is still poor especially for metastatic, high-grade, and relapsed RMS. New treatments are urgently needed, especially systemic therapies. Chimeric Antigen Receptor T cells (CAR Ts) are very effective against hematological malignancies, but ...
Andrea Timpanaro   +7 more
openaire   +1 more source

CD276-positive circulating endothelial cells in advanced colorectal cancer.

Journal of Clinical Oncology, 2019
572 Background: The value of circulating endothelial cells (CECs) as predictive biomarker in metastatic colorectal cancer (mCRC) may be improved by using tumor-derived CECs. CD276 can discriminate between tumor derived and normal CECs. We evaluated whether CD276+CEC is a clinically relevant biomarker with 100% sensitivity to predict response to first
Elske C. Gootjes   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy